Menu Search
Equities

Sartorius Stedim Biotech SA

56S1:BER

Sartorius Stedim Biotech SA

Actions
  • Price (EUR)207.20
  • Today's Change4.70 / 2.32%
  • Shares traded10.00
  • 1 Year change-14.31%
  • Beta--
Data delayed at least 15 minutes, as of May 03 2024 07:04 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sartorius Stedim Biotech SA is a France-based international provider of laboratory and process technologies and equipment. The Company covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The Company operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.

  • Revenue in EUR (TTM)2.72bn
  • Net income in EUR254.70m
  • Incorporated1978
  • Employees10.60k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		DIM:PAR since
announced		Transaction
value
Polyplus Transfection SAAnnounced18 Jul 202318 Jul 2023Announced-9.08%--
Data delayed at least 15 minutes, as of May 03 2024 16:35 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.